HAE
HAEMONETICS CORP
NYSE · Healthcare · Medical - Instruments & Supplies · US
$118.41
−0.27%Year over year
Reported trailing growth
- Revenue
- +0.4%
- EBITDA
- -30.7%
- EBIT
- +13.7%
- EPS
- -37.4%
- Free cash flow
- +53.9%
- Operating cash flow
- +44.9%
Forward estimates
Based on analyst estimates
- Revenue
- +7.9%
- EBITDA
- +80.8%
- EPS
- +174.1%
Three-year CAGR
- Revenue
- +4.5%
- EBITDA
- +1.0%
- EBIT
- +15.7%
- Net income
- -5.5%
- EPS
- -3.3%
- Free cash flow
- +16.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026